<p>Mumbai, Baltimore, April 10, 2019: Pharma major Lupin Limited (Lupin) announced the launch of Fluoxetine Tablets USP, 60mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.</p><p>Lupin&amp;rsquo;s Fluoxetine Tablets USP, 60mg, is the generic version of Alvogen Group Holdings 3 LLC&amp;rsquo;s Fluoxetine Tablets, 60mg. It is indicated in the treatment of:</p><p><strong>Major Depressive Disorder (MDD)</strong></p><p><strong>Adults:</strong> Efficacy was established in one 5-week trial, three 6-week trials, and one maintenance study</p><p><strong>Pediatrics:</strong> Efficacy was established in two 8- to 9-week trials of patients 8 to 18 years of age</p><p><strong>Obsessive Compulsive Disorder (OCD)</strong></p><p><strong>Adults: </strong>Efficacy was established in two 13-week trials</p><p><strong>Pediatrics:</strong> Efficacy was established in one 13-week trial in pediatric patients 7 to 17 years of age</p><p><strong>Bulimia Nervosa</strong></p><p><strong>Adults:</strong> Efficacy was established in two 8-week trials and one 16-week trial</p><p><strong>Panic disorder, with or without agoraphobia</strong></p><p><strong>Adults:</strong> Efficacy was established in two 12-week trials</p><p>Fluoxetine Tablets, 60mg, had annual sales of approximately USD 41 million in the US (IQVIA MAT February 2019).</p>